

Sepsis Committee meeting 11

Date: 08/09/15

Location: Boardroom, NCGC, 180 Great Portland Street, London, W1W 5QZ

Minutes: Confirmed

Committee members present:

Saul Faust (Chair)	Professor of Paediatric Immunology & Infectious Diseases & Director, NIHR Wellcome Trust Clinical Research Facility, University of Southampton
Richard Beale	Clinical Director of Perioperative, Critical Care & Pain Services and Consultant in Intensive Care Medicine
John Butler	Consultant in Emergency Medicine & Critical Care Medicine
Enitan Carrol	Chair in Paediatric Infection/Honorary Consultant, University of Liverpool Institute of Infection and Global Health
Simon Nadel	Adjunct Professor of Paediatric Intensive Care
Jenny O'Donnell	Patient member
Rachel Rowlands	Consultant in Paediatric Emergency Medicine
Mark Simmonds	Consultant in Acute and Critical Care Medicine
Alison Tavare	General Practitioner
Louella Vaughan	Senior Clinical Research Lead, Northwest London CLAHRC
James Wenman	Clinical Development Manager
Catherine White	Patient member

Technical team:

Mikaela Bartlett	Document Editor/Process Assistant, NCGC
Margaret Constanti	Senior Health Economist, NCGC
Andreas Freitag	Research Fellow, NCGC
Lina Gulhane	Joint Head of Information Science and Knowledge Manager, NCGC
Norma O'Flynn	Clinical Director and Deputy Chief Operating Officer, NCGC
Nancy Pursey	Senior Project Manager, NCGC

Silvia Rabar	Senior Research Fellow, NCGC
Ashwini Sreekanta	Research Fellow, NCGC

Observers:

Francesca Fasesin	Research Fellow, NCGC
-------------------	-----------------------

NICE:

Caroline Keir	NICE Commissioning Manager
---------------	----------------------------

Apologies:

Neil Askew	Health Economist, NCGC
Angela Cooper	Senior Research Fellow, NCGC
Julian Newell	Corporate Matron, Patient Safety

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 11th meeting on Sepsis. The Committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: pathways and traffic light system updates, plus review questions on early goal-directed therapy, inotropic agents, monitoring, escalation of care and discussing recommendations for central venous access and arterial lines. Research recommendations and putting the guideline together were also objectives for the meeting.

Introductions

The Chair welcomed NP and MB from the technical team to the Committee.

2. Declarations of interest

The Chair asked everyone to verbally declare any conflicts of interest that have arisen since the last meeting.

- Name: Saul Faust – Personal pecuniary interest and personal non-pecuniary interest
- Name: Mark Simmonds –Personal non-financial specific
- Name: Alison Tavaré – Personal non-pecuniary interest
- Name: Simon Nadal – Personal non-pecuniary interest

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Traffic light system and pathways

The Committee discussed non-acute care and hospital care pathways and traffic light system. They were given the opportunity to ask questions.

5. Questions and discussion

AS presented the clinical evidence for the Early goal-directed therapy review and MC presented the economic evidence. The Committee then discussed the evidence.

AF presented the clinical evidence for the Inotropic agents review and MC presented the economic evidence. The Committee then discussed the evidence.

SR presented the clinical evidence for the Monitoring review and MC presented the economic evidence. The Committee then discussed the evidence.

AF presented the clinical evidence for the Escalation of care review and MC presented the economic evidence. The Committee then discussed the evidence.

The Committee discussed Central venous access and arterial lines, as there was no review for this question.

6. Other issues

The Committee discussed the research recommendations for the guideline.

NOF presented the section on Writing the guideline and advised the Committee how to proceed.

7. Any other business
No other business to discuss.

Date of next meeting: 18/09/15

Location of next meeting: Boardroom, NCGC, 180 Great Portland Street,
London, W1W 5QZ